The UK drug regulator approved AstraZeneca, which is based on COVID-19 antibodies, and is used to prevent infection in people with a weak immune response. Evusheld contains antibodies made in a laboratory that are designed to persist in the body for months to stop the virus in the event of an infection.

The approval decision for Evusheld was approved by the government's independent scientific advisory body. And although 85 percent. In British people over 12 years of age who have been vaccinated with two doses, some people with immunosuppression or a history of serious adverse reactions due to vaccination may need alternative protection against the coronavirus. "While COVID-19 vaccines continue to be the first line of defense against COVID-19, we know that some people may not be responding adequately," said MHRA chief June Raine. The studies confirmed that the treatment reduced the risk of symptomatic COVID-19 by 77%, and the protection against the virus lasted at least six months after a single dose. Evusheld has also been shown to save lives and prevent disease progression when given within one week of the first symptoms of coronavirus infection.

AstraZeneca hopes the therapy will be made available to the British as soon as possible. Currently, Evusheld is under review in Europe and has been approved in the United States. Treatment given by intramuscular injection should not be used in people infected with the SARS-CoV-2 virus or who have had recent contact with an infected person.

The regulator noted that there is insufficient data to fully assess the effectiveness of the therapy against the highly contagious variant of Omicron.

Source: Reuters